Skip to main content
. 2019 Jun 21;30(7):1206–1219. doi: 10.1681/ASN.2018121254

Figure 1.

Figure 1.

Desensitization with daratumumab and plerixafor reduces donor-specific alloantibody significantly in sensitized NHPs. (A) Schematic representation of sensitization and desensitization. Maximally MHC-mismatched NHP pairs received two serial skin transplants for sensitization and desensitization treatment or no treatment (control group) before kidney transplantation. (B) The absolute number of peripheral white blood cells and immune cell population. (C) Effect of DPT on peripheral B cells. B cell subpopulations, including CD20+ B cells, IgG+ B cells, and IgG+CD27+ B cells, were not changed. (D) The frequency of naive, central memory, effector memory CD4, and CD8 T cells were not changed with DPT. (E) Desensitization with daratumumab and plerixafor reduces DSA significantly compared with control. DSA levels were measured by T cell flow crossmatch and shown as MFI shift. *P<0.05. (F) Representative normalized MFI of single antigen bead testing before and after DPT. NHP serum samples were evaluated with HLA single antigen bead assay. BASO, basophil; EO, eosinophil; LN/BM, lymph node/bone marrow; LYMPH, lymphocyte; MONO, monocyte; NEUT, neutrophil; Tcm, central memory T cell; Tem, effector memory T cell; Tn, naive T cell; Tx, transplant; WBC, white blood cell.